ArticleNature medicine2018

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.

Jacqulyne P Robichaux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.